|Bid||106.35 x 900|
|Ask||106.53 x 800|
|Day's Range||104.24 - 109.86|
|52 Week Range||28.00 - 131.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.09|
President Joe Biden confirmed late Tuesday that drug giant Merck will step in to help its rival, supply-constrained Johnson and Johnson, manufacture its much-needed coronavirus vaccine.
The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.
France has used only a quarter of its AstraZeneca COVID-19 vaccine doses, a health ministry official indicated on Tuesday, saying its utilisation rate stood at 24% as of Feb. 28, well below a target set at 80-85%. This compares with 82% for vaccines made by Pfizer/BioNTech and 37% for those made by Moderna. "It is true that we are facing issues with AstraZeneca vaccines," the official said without elaborating.